SRC
GSK icon

Sage Rhino Capital’s GSK GSK Stock Holding History

Sage Rhino Capital’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$395K Buy
7,149
+246
+4% +$13.3K 0.07% 165
2025
Q4 		$339K Sell
6,903
-2
-0% -$93 0.06% 181
2025
Q3 		$298K Buy
6,905
+293
+4% +$11.4K 0.06% 195
2025
Q2 		$254K Buy
6,612
+225
+4% +$8.6K 0.05% 200
2025
Q1 		$247K Buy
6,387
+156
+3% +$5.71K 0.06% 196
2024
Q4 		$211K Buy
6,231
+46
+0.7% +$1.66K 0.05% 234
2024
Q3 		$253K Buy
6,185
+109
+2% +$4.46K 0.06% 199
2024
Q2 		$234K Sell
6,076
-444
-7% -$18.7K 0.06% 197
2024
Q1 		$280K Buy
6,520
+178
+3% +$7.34K 0.07% 173
2023
Q4 		$235K Sell
6,342
-238
-4% -$8.54K 0.06% 184
2023
Q3 		$239K Buy
+6,580
New +$234K 0.07% 180
2022
Q3 		– Sell
-6,335
Closed -$345K – 197
2022
Q2 		$345K Buy
6,335
+151
+2% +$8.34K 0.13% 130
2022
Q1 		$337K Buy
6,184
+326
+6% +$17.7K 0.1% 154
2021
Q4 		$323K Buy
5,858
+788
+16% +$41K 0.09% 156
2021
Q3 		$242K Buy
5,070
+364
+8% +$18.3K 0.07% 169
2021
Q2 		$234K Buy
+4,706
New +$226K 0.07% 172
2020
Q4 		– Sell
-4,554
Closed -$214K – 182
2020
Q3 		$214K Buy
4,554
+452
+11% +$22.6K 0.1% 142
2020
Q2 		$209K Buy
+4,102
New +$210K 0.11% 144
2020
Q1 		– Sell
-4,104
Closed -$240K – 152
2019
Q4 		$240K Buy
4,104
+269
+7% +$15K 0.14% 126
2019
Q3 		$205K Buy
+3,835
New +$197K 0.13% 131

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Sage Rhino Capital's GSK Position: Q1 2026 in Review

Sage Rhino Capital increased its GSK (GSK) stake by 3.6% in Q1 2026, buying an estimated $13.3K and bringing the position to 7,149 shares worth $395K. The position accounts for 0.07% of the portfolio, ranked #165.

Sage Rhino Capital first reported a position in GSK in Q3 2019 and has held it in 20 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Sage Rhino Capital held 7,149 shares of GSK worth $395K as of Q1 2026.
  • Sage Rhino Capital bought 246 GSK shares in Q1 2026, an estimated $13.3K.
  • GSK made up 0.07% of Sage Rhino Capital's portfolio in Q1 2026, its #165 holding.
  • Sage Rhino Capital first reported a position in GSK in Q3 2019 and has held it in 20 quarters since.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Sage Rhino Capital's 13F filing for Q1 2026, filed 28 Apr 2026.